Boston Scientific Corporation

BSX · NYSE · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$443K – $1.8M 28 disclosures · 17 bought / 11 sold · last Aug 28, 2026
Ro Khanna D · HOUSE · CA	−$413K – $588K −$366K – $584K today 58 filings · last Aug 10, 2026
Markwayne Mullin R · SENATE · OK	$31K – $115K $21K – $80K today 3 filings · last Dec 29, 2025
Michael T. McCaul R · HOUSE · TX	−$974K – $1.1M −$796K – $1.3M today 49 filings · last Apr 24, 2024
Alan S. Lowenthal D · HOUSE · CA	−$56K – $126K −$58K – $186K today 16 filings · last Oct 24, 2022
Alan Armstrong R · SENATE · OK	$1K – $15K $661 – $10K today 1 filing · last Mar 27, 2026
Gilbert Ray Cisneros, Jr. D · HOUSE · CA	−$125K – $141K −$60K – $118K today 19 filings · last Aug 18, 2026
Thad Cochran R · HOUSE · MS	−$14K – $14K −$37K – $36K today 2 filings · last Jun 15, 2015
Bruce Westerman R · HOUSE · AR	−$14K – $14K −$7K – $6K today 2 filings · last Apr 21, 2025
Bob Corker R · HOUSE · TN	−$14K – $14K −$51K – $50K today 2 filings · last May 20, 2014

Recent transactions

Trades from Mar 27, 2026 – Aug 28, 2026

Politician	Type	Filed after	Amount
Donald Trump R · EXECUTIVE	Buy	41 days Aug 28, 2026 → Oct 8, 2026	≥$15K
Donald Trump R · EXECUTIVE	Buy	52 days Aug 17, 2026 → Oct 8, 2026	≥$15K
Donald Trump R · EXECUTIVE	Buy	59 days Aug 10, 2026 → Oct 8, 2026	≥$1K
Kevin Hern R · HOUSE · OK-1	Sell	16 days Sep 9, 2026 → Sep 25, 2026	≥$50K
Kevin Hern R · HOUSE · OK-1	Sell	21 days Sep 4, 2026 → Sep 25, 2026	≥$50K
Kevin Hern R · HOUSE · OK-1	Sell	22 days Sep 3, 2026 → Sep 25, 2026	≥$1K
Kevin Hern R · HOUSE · OK-1	Sell	25 days Aug 31, 2026 → Sep 25, 2026	≥$15K
Donald Trump R · EXECUTIVE	Buy	57 days Jul 27, 2026 → Sep 22, 2026	≥$50K
Donald Trump R · EXECUTIVE	Buy	60 days Jul 24, 2026 → Sep 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	61 days Jul 23, 2026 → Sep 22, 2026	≥$50K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

1,580

13F shares

1.34B

Total invested

$57.7B

Ownership

90.6%

New positions

155

Closed positions

346

Increased positions

742

Reduced positions

622

Put/Call ratio

0.43

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	129.7M	$5.5B	−1.62%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	97.1M	$4.1B	+0.70%
STATE STREET CORP	9/22/2026	70.1M	$3.0B	+3.12%
PRIMECAP MANAGEMENT CO/CA/	8/14/2026	50.5M	$2.2B	+55.31%
FMR LLC	8/13/2026	45.7M	$2.0B	−38.43%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	8/3/2026	24.9M	$1.5B	+126.06%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	33.4M	$1.4B	+0.46%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	29.8M	$1.3B	−0.01%
D. E. SHAW & CO., INC.	8/14/2026	25.5M	$1.1B	+4.71%
JPMORGAN CHASE & CO	8/12/2026	23.9M	$1.0B	−28.31%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	8/13/2026	23.3M	$994.2M	+67.68%
NORGES BANK	8/12/2026	21.2M	$903.5M	—
TWO SIGMA INVESTMENTS, LP	8/14/2026	19.4M	$826.2M	+105.70%
MORGAN STANLEY	8/13/2026	18.9M	$808.7M	−14.91%
JUPITER TOPCO LLC	8/14/2026	18.8M	$803.4M	—
BOLLARD GROUP LLC	8/12/2026	18.4M	$786.2M	−0.60%
GOLDMAN SACHS GROUP INC	8/14/2026	17M	$723.6M	−10.25%
CAPITAL WORLD INVESTORS	8/12/2026	16.8M	$717.6M	+9.81%
UBS GROUP AG	8/13/2026	16.4M	$697.9M	+10.31%
JANE STREET GROUP, LLC	8/14/2026	16.1M	$686.6M	+765.06%
WELLINGTON MANAGEMENT GROUP LLP	8/14/2026	15.3M	$653.1M	−18.75%
AMUNDI	8/11/2026	14.3M	$610.2M	+1.23%
CAPITAL RESEARCH GLOBAL INVESTORS	8/12/2026	14.2M	$605.3M	+100.27%
INVESCO LTD.	8/14/2026	13.8M	$589.0M	+52.46%
FRANKLIN RESOURCES INC	8/13/2026	13.8M	$587.8M	−5.01%

Insider transactions

Insider	Type	Transacted	Price	Date
O'Connor Padraig Andrew	F-INKIND	567	$48.37	Sep 2
O'Connor Padraig Andrew	M-EXEMPT	1.2K	—	Sep 2
O'Connor Padraig Andrew	M-EXEMPT	1.2K	—	Sep 2
Morano Susan E	P-PURCHASE	2K	$49.22	Aug 25
Woodworth Emily	I-DISCRETIONARY	2.9K	$51.19	Aug 11
Monson Jonathan	I-DISCRETIONARY	9.9K	$50.46	Aug 10
Habiger David C	P-PURCHASE	2.1K	$47.59	Aug 5
Habiger David C	P-PURCHASE	140	$48.59	Aug 4
Mahoney Michael F	I-DISCRETIONARY	22.1K	$48.43	Aug 3
Mahoney Michael F	P-PURCHASE	186.2K	$48.33	Aug 3

Analyst consensus

Buy44 analysts

Bearish · 0 · Hold · 7 · Bullish · 37

Earnings history

	EPS	Estimate
Q3 2024	$0.63	$0.59	Beat
Q4 2024	$0.70	$0.66	Beat
Q1 2025	$0.75	$0.67	Beat
Q2 2025	$0.75	$0.72	Beat
Q3 2025	$0.75	$0.71	Beat
Q4 2025	$0.80	$0.78	Beat
Q1 2026	$0.80	$0.79	Beat
Q2 2026	$0.86	$0.83	Beat

Peers

Company overview

IPO dateMay 19, 1992

CEOMichael F. Mahoney

Employees59,000

SectorHealthcare

IndustryMedical - Devices

CountryUS

ExchangeNew York Stock Exchange

Websitewww.bostonscientific.com

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.